STING1 and cancer: Furthermore, PARP inhibitors have been found to stimulate the STING pathway, enhancing tumor antigenicity and promoting the infiltration of intratumoral T cells across different cancer types from an immunological standpoint.181,846 It has been crucially uncovered that PARP inhibitors can boost the levels of PD-L1 expression in breast cancer cell lines and mouse tumor models.